{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:48:00Z","timestamp":1793321280805,"version":"4.5.0"},"reference-count":52,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T00:00:00Z","timestamp":1638403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Nasopharyngeal carcinoma (NPC) is a rare cancer of the nasopharyngeal mucosa with a specific geographic predisposition. NPC is often associated with Epstein\u2013Barr Virus (EBV) infection and as a result contains many characteristic biomarkers. Treatment of locally-contained NPC is generally achieved through use of radiotherapy (RT), as part of a multimodality treatment regimen. Induction chemotherapy followed by concurrent RT and platinum-based chemotherapy regimen has emerged as the definitive treatment of choice for locoregionally-advanced NPC. Recently, immunotherapy is finding a role in the treatment of recurrent or metastatic NPC. Immune checkpoint blockade therapies targeted against the programmed death-1 (PD-1) receptor have demonstrated efficacy in early phase clinical trials, with ongoing phase III trials in effect. Biomarkers for treatment efficacy remain an ongoing area of investigation, with important prognostic implications on the horizon.<\/jats:p>","DOI":"10.3390\/cancers13236078","type":"journal-article","created":{"date-parts":[[2021,12,2]],"date-time":"2021-12-02T21:19:08Z","timestamp":1638479948000},"page":"6078","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Multimodality Management of EBV-Associated Nasopharyngeal Carcinoma"],"prefix":"10.3390","volume":"13","author":[{"given":"Justin","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Pham","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narine","family":"Wandrey","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mackenzie","family":"Daly","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana","family":"Karam","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41588-019-0436-5","article-title":"Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma","volume":"51","author":"Xu","year":"2019","journal-title":"Nat. Genet."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1016\/j.ijrobp.2004.05.022","article-title":"Treatment of nasopharyngeal carcinoma with intensity-modulated radiotherapy: The Hong Kong experience","volume":"60","author":"Kam","year":"2004","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.oraloncology.2015.08.005","article-title":"Intensity-modulated radiation therapy versus 2D-RT or 3D-CRT for the treatment of nasopharyngeal carcinoma: A systematic review and meta-analysis","volume":"51","author":"Zhang","year":"2015","journal-title":"Oral Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"E2130","DOI":"10.1002\/hed.23977","article-title":"Evidence on effectiveness of intensity-modulated radiotherapy versus 2-dimensional radiotherapy in the treatment of nasopharyngeal carcinoma: Meta-analysis and a systematic review of the literature","volume":"38","author":"Co","year":"2016","journal-title":"Head Neck"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.ijrobp.2008.07.062","article-title":"Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging","volume":"73","author":"Mao","year":"2009","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099","volume":"16","author":"LeBlanc","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijrobp.2005.06.037","article-title":"Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients","volume":"64","author":"Baujat","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(15)70126-9","article-title":"Chemotherapy and radiotherapy in nasopharyngeal carcinoma: An update of the MAC-NPC meta-analysis","volume":"16","author":"Blanchard","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.oraloncology.2019.06.015","article-title":"Induction chemotherapy in head and neck cancers: Results and controversies","volume":"95","author":"Gau","year":"2019","journal-title":"Oral Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdy102","article-title":"Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: Role, controversy, and future directions","volume":"29","author":"Haddad","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/hed.24694","article-title":"Neoadjuvant chemotherapy in geriatric head and neck cancers","volume":"39","author":"Patil","year":"2017","journal-title":"Head Neck"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2008.18.1545","article-title":"Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma","volume":"27","author":"Hui","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/annonc\/mdr116","article-title":"Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma: A randomized phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG)","volume":"23","author":"Fountzilas","year":"2012","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.ijrobp.2015.01.002","article-title":"Concurrent chemo-radiation with or without induction gemcitabine, Carboplatin, and Paclitaxel: A randomized, phase 2\/3 trial in locally advanced nasopharyngeal carcinoma","volume":"91","author":"Tan","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1093\/annonc\/mdx770","article-title":"A randomized trial of induction docetaxel-cisplatin-5FU followed by concomitant cisplatin-RT versus concomitant cisplatin-RT in nasopharyngeal carcinoma (GORTEC 2006-02)","volume":"29","author":"Frikha","year":"2018","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","article-title":"Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma","volume":"381","author":"Zhang","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102973","DOI":"10.1016\/j.amjoto.2021.102973","article-title":"Survival benefit of induction chemotherapy in treatment for stage III or IV locally advanced nasopharyngeal carcinoma\u2014An updated meta-analysis and systematic review","volume":"42","author":"Hu","year":"2021","journal-title":"Am. J. Otolaryngol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJMoa070956","article-title":"Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer","volume":"357","author":"Posner","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/CAD.0000000000000867","article-title":"Induction treatment prior to chemoradiotherapy in nasopharyngeal carcinoma: Triplet or doublet chemotherapy?","volume":"31","author":"Hennessy","year":"2020","journal-title":"Anticancer Drugs"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0140-6736(19)30956-0","article-title":"Nasopharyngeal carcinoma","volume":"394","author":"Chen","year":"2019","journal-title":"Lancet"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Huang, S.C.M., Tsao, S.W., and Tsang, C.M. (2018). Interplay of Viral Infection, Host Cell Factors and Tumor Microenvironment in the Pathogenesis of Nasopharyngeal Carcinoma. Cancers, 10.","DOI":"10.3390\/cancers10040106"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12943-020-01292-5","article-title":"Unraveling tumour microenvironment heterogeneity in nasopharyngeal carcinoma identifies biologically distinct immune subtypes predicting prognosis and immunotherapy responses","volume":"20","author":"Chen","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1002\/hed.25189","article-title":"Prognostic stratification of patients with nasopharyngeal carcinoma based on tumor immune microenvironment","volume":"40","author":"Ono","year":"2018","journal-title":"Head Neck"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1158\/1541-7786.MCR-17-0134","article-title":"Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes","volume":"15","author":"Zhang","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0140-6736(15)00055-0","article-title":"Nasopharyngeal carcinoma","volume":"387","author":"Chua","year":"2016","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1158\/0008-5472.CAN-12-2448","article-title":"Phase I trial of recombinant modified vaccinia ankara encoding Epstein-Barr viral tumor antigens in nasopharyngeal carcinoma patients","volume":"73","author":"Hui","year":"2013","journal-title":"Cancer Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","article-title":"A recombinant modified vaccinia ankara vaccine encoding Epstein-Barr Virus (EBV) target antigens: A phase I trial in UK patients with EBV-positive cancer","volume":"20","author":"Taylor","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"12189","DOI":"10.18632\/oncotarget.2608","article-title":"EBV-driven LMP1 and IFN-\u03b3 up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy","volume":"5","author":"Fang","year":"2014","journal-title":"Oncotarget"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev.immunol.20.091101.091806","article-title":"The B7 family of ligands and its receptors: New pathways for costimulation and inhibition of immune responses","volume":"20","author":"Carreno","year":"2002","journal-title":"Annu. Rev. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.1200\/JCO.2017.73.3675","article-title":"Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study","volume":"35","author":"Hsu","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1200\/JCO.2017.77.0388","article-title":"Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)","volume":"36","author":"Ma","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(18)30495-9","article-title":"Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: Results from two single-arm, phase 1 trials","volume":"19","author":"Fang","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"LBA2","DOI":"10.1200\/JCO.2021.39.15_suppl.LBA2","article-title":"JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC)","volume":"39","author":"Xu","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/sj.onc.1209839","article-title":"The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation","volume":"26","author":"Seng","year":"2007","journal-title":"Oncogene"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1038\/sj.onc.1209154","article-title":"Functional epigenetics identifies a protocadherin PCDH10 as a candidate tumor suppressor for nasopharyngeal, esophageal and multiple other carcinomas with frequent methylation","volume":"25","author":"Ying","year":"2006","journal-title":"Oncogene"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Han, B., Yang, X., Zhang, P., Zhang, Y., Tu, Y., He, Z., Li, Y., Yuan, J., Dong, Y., and Hosseini, D.K. (2020). DNA methylation biomarkers for nasopharyngeal carcinoma. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230524"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1158\/1535-7163.MCT-15-0260","article-title":"Genome-Wide Identification of a Methylation Gene Panel as a Prognostic Biomarker in Nasopharyngeal Carcinoma","volume":"14","author":"Jiang","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2016.04.006","article-title":"MicroRNAs serving as potential biomarkers and therapeutic targets in nasopharyngeal carcinoma: A critical review","volume":"103","author":"Lee","year":"2016","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_41","first-page":"1305","article-title":"microRNA-222 promotes tumor growth and confers radioresistance in nasopharyngeal carcinoma by targeting PTEN","volume":"17","author":"Wu","year":"2018","journal-title":"Mol. Med. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.bbrc.2013.12.095","article-title":"MicroRNA-7 arrests cell cycle in G1 phase by directly targeting CCNE1 in human hepatocellular carcinoma cells","volume":"443","author":"Zhang","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1038\/s41598-020-61958-4","article-title":"Identification of non-invasive biomarkers for predicting the radiosensitivity of nasopharyngeal carcinoma from serum microRNAs","volume":"10","author":"Li","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1533033818793652","DOI":"10.1177\/1533033818793652","article-title":"MicroRNA-19b Promotes Nasopharyngeal Carcinoma More Sensitive to Cisplatin by Suppressing KRAS","volume":"17","author":"Zhang","year":"2018","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S1470-2045(12)70102-X","article-title":"Prognostic value of a microRNA signature in nasopharyngeal carcinoma: A microRNA expression analysis","volume":"13","author":"Liu","year":"2012","journal-title":"Lancet Oncol."},{"key":"ref_46","first-page":"1767","article-title":"The four-microRNA signature identified by bioinformatics analysis predicts the prognosis of nasopharyngeal carcinoma patients","volume":"42","author":"Zhang","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_47","first-page":"1188","article-title":"Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma","volume":"59","author":"Lo","year":"1999","journal-title":"Cancer Res."},{"key":"ref_48","first-page":"6878","article-title":"Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA","volume":"60","author":"Lo","year":"2000","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/jnci\/94.21.1614","article-title":"Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma","volume":"94","author":"Chan","year":"2002","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1056\/NEJMoa032260","article-title":"Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma","volume":"350","author":"Lin","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ijrobp.2019.01.007","article-title":"Plasma Epstein-Barr Virus DNA Load After Induction Chemotherapy Predicts Outcome in Locoregionally Advanced Nasopharyngeal Carcinoma","volume":"104","author":"Huang","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Chan, A.T.C., Hui, E.P., Ngan, R.K.C., Tung, S.Y., Cheng, A.C.K., Ng, W.T., Lee, V.H.F., Ma, B.B.Y., Cheng, H.C., and Wong, F.C.S. (2018). Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial. J. Clin. Oncol., JCO2018777847.","DOI":"10.1200\/JCO.2018.77.7847"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/23\/6078\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:38:51Z","timestamp":1760168331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/23\/6078"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,2]]},"references-count":52,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["cancers13236078"],"URL":"https:\/\/doi.org\/10.3390\/cancers13236078","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,2]]}}}